We are live on ! Find out more
LVTX

LAVA Therapeutics
LVTX

Delisted

LVTX was delisted on the 20th of November, 2025.

Back to rankings

17 hedge funds and large institutions have $22.8M invested in LAVA Therapeutics in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 8 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.61% less ownership

Funds ownership: 31.01% → 30.41% (-0.61%)

6% less funds holding

Funds holding: 18 → 17 (-1)

35% less capital invested

Capital invested by funds: $35.2M → $22.8M (-$12.4M)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

88% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 8

Holders
17
Holders Change
-1
Holders Change %
-5.56%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
8
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CC
Cannell Capital
Wyoming
+$14.1K
2
Morgan Stanley
Morgan Stanley
New York
+$10.1K

Top Sellers

Rank Fund Capital Flow
1
NIP
Nicholas Investment Partners
California
-$254K
2
Millennium Management
Millennium Management
New York
-$188K
3
NCM
Nantahala Capital Management
Connecticut
-$38.8K
4
DCM
DAFNA Capital Management
California
-$38.1K
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$17.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
NHAS
1
Novo Holdings A/S
Denmark
$9.82M – – –
RG
2
Redmile Group
California
$8.05M – – –
NIP
3
Nicholas Investment Partners
California
$1.29M -$254K -73,364 -14%
NCM
4
Nantahala Capital Management
Connecticut
$953K -$38.8K -11,184 -3%
Axa
5
Axa
France
$671K -$15.3K -4,413 -2%
AG
6
Artal Group
Luxembourg
$590K – – –
DCM
7
DAFNA Capital Management
California
$379K -$38.1K -10,997 -8%
AWG
8
Alpha Wave Global
New York
$347K – – –
Point72 Asset Management
9
Point72 Asset Management
Connecticut
$330K -$17.3K -4,988 -4%
Millennium Management
10
Millennium Management
New York
$276K -$188K -54,225 -36%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$45K -$8.58K -2,474 -14%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$31K – – –
Morgan Stanley
13
Morgan Stanley
New York
$17K +$10.1K +2,900 +104%
CC
14
Cannell Capital
Wyoming
$12K +$14.1K +4,058 New
UBS Group
15
UBS Group
Switzerland
$1K -$2.84K -820 -67%
TFGT
16
TS Financial Group (TSFG)
Illinois
$1K – – –
PHK
17
Point72 Hong Kong
Hong Kong
– -$3K -631 Closed

LVTX Hedge Fund Activity: Q2 2022 in Review

17 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q2 2022, worth a combined $22.8M — down 35% from $35.2M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of LVTX and 1 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 1 added.

The largest buyer was Cannell Capital, opening a new position worth an estimated $14.1K. The largest seller was Nicholas Investment Partners, cutting an estimated $254K.

  • 17 institutional investors held LAVA Therapeutics (LVTX) as of Q2 2022, down from 18 in Q1 2022.
  • Funds reported $22.8M of LAVA Therapeutics stock for Q2 2022, down 35% quarter-over-quarter.
  • 1 fund opened new LAVA Therapeutics positions in Q2 2022 and 2 closed out, a net change of -1 holder.
  • The largest LAVA Therapeutics buyer in Q2 2022 was Cannell Capital, an estimated $14.1K added.
  • The largest LAVA Therapeutics seller in Q2 2022 was Nicholas Investment Partners, an estimated $254K sold.

Based on aggregated 13F filings for Q2 2022.